Annual Drug Patent Expirations for SAVELLA
Savella is a drug marketed by Allergan and is included in one NDA. It is available from two suppliers. There are two patents protecting this drug and one Paragraph IV challenge.
Drug patent litigation for SAVELLA.
This drug has forty-seven patent family members in twenty-seven countries.
The generic ingredient in SAVELLA is milnacipran hydrochloride. Two suppliers are listed for this compound. Additional details are available on the milnacipran hydrochloride profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
